# A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

> **NCT03299842** · PHASE3 · TERMINATED · sponsor: **Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** ZX008 (Fenfluramine Hydrochloride)

## Key facts

- **NCT ID:** NCT03299842
- **Lead sponsor:** Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-12
- **Primary completion:** 2018-07-05
- **Final completion:** 2018-07-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was stopped due to low enrollment.
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299842, "A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03299842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*